Header Logo

Connection

DOV KADMON to Prostatic Neoplasms, Castration-Resistant

Back to Details
This is a "connection" page, showing publications DOV KADMON has written about Prostatic Neoplasms, Castration-Resistant.
DOV KADMON
Connection Strength
0.092
Prostatic Neoplasms, Castration-Resistant
  1. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242.
    View in: PubMed
    Score: 0.092
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.